CureVac NV (WBO:CVAC) Net Cash per Share : €1.02 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). CureVac NV's Net Cash per Share for the quarter that ended in Sep. 2023 was €1.02.

The historical rank and industry rank for CureVac NV's Net Cash per Share or its related term are showing as below:

WBO:CVAC' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14 Med: 9.75 Max: 86.7
Current: 2.22

During the past 5 years, the highest Price-to-Net-Cash Ratio of CureVac NV was 86.70. The lowest was 2.14. And the median was 9.75.

WBO:CVAC's Price-to-Net-Cash is ranked better than
69.09% of 867 companies
in the Biotechnology industry
Industry Median: 3.87 vs WBO:CVAC: 2.22

CureVac NV Net Cash per Share Historical Data

The historical data trend for CureVac NV's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Net Cash per Share Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Net Cash per Share

-0.19

-0.80

2.91

1.85

0.89

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Net Cash per Share	Get a 7-Day Free Trial														1.36	0.89	1.61	1.31	1.02

Competitive Comparison of CureVac NV's Net Cash per Share

For the Biotechnology subindustry, CureVac NV's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where CureVac NV's Price-to-Net-Cash falls into.

CureVac NV Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

CureVac NV's Net Cash per Share for the fiscal year that ended in Dec. 2022 is calculated as

	Net Cash per Share (A: Dec. 2022 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(500.284	-	327.219	-	0)	/	194.954
=	0.89

CureVac NV's Net Cash per Share for the quarter that ended in Sep. 2023 is calculated as

	Net Cash per Share (Q: Sep. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(467.6	-	240.301	-	0)	/	223.924
=	1.02

CureVac NV (WBO:CVAC) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

CureVac NV Net Cash per Share Related Terms

Thank you for viewing the detailed overview of CureVac NV's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.